Watch Intro to Ra Pharma and Zilucoplan for potential treatment of IMNM

Ben Matys, Sr. Clinical Trial Manager, and Ramin Farzaneh-Far, Chief Medical Officer of Ra Pharma, joined Myositis Support and Understanding (MSU) on Wednesday, November 6, 2019, for a live webinar, “Introduction to Ra Pharma & the Potential of Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy (IMNM)”

This video (above) with discussion provides a great overview of IMNM and the complement pathway, information about the Phase 2 Study including locations, with a travel assistance program, and a Q&A session.

Presentation Slides

View/Download the presentation slides. Share these with your physician if you are eligible and interested in participating in this Phase 2 clinical trial.

About IMNM

Learn more about immune-mediated necrotizing myopathy (IMNM), sometimes called necrotizing autoimmune myopathy (NAM).

Learn more about Ra Pharma

Visit the Ra Pharma website to learn more about the company, pipeline, and more.

See more educational myositis videos

Tags:

Author:

Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy

MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

Login with your credentials

or    

Forgot your details?

Register for Membership

Send this to a friend